Contribute Try STAT+ Today

On the eve of a closely watched trial, Teva Pharmaceutical (TEVA) agreed to pay $85 million to settle charges made by the state of Oklahoma of fueling the opioid crisis by overstating the benefits of its opioid painkillers and downplaying addictive risks that led doctors to prescribe the drugs unnecessarily.

The agreement, which must still be finalized, was announced on Sunday, just two days before a trial is scheduled to get underway. However, Oklahoma Attorney General Mike Hunter said the trial will continue as planned against Johnson & Johnson (JNJ), which faces the same claims. Several weeks ago, Purdue Pharma agreed to pay $270 million to settle allegations by the state.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.